BSE filing, NSE: SYMBIOTEC. Summary written from the filing by ALFA Finder's alert engine.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,246.30
- Market cap
- ₹8,008 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab schedules a 5 November 2026 board meeting to consider unaudited quarterly and half-year results. No amounts are proposed.
Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31 of the SEBI LODR Regulations.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab has filed the routine quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending September 30, 2026.
Symbiotec Pharmalab Other Announcement
Designated persons of Symbiotec Pharmalab sold equity shares worth ₹11.94 crore in the open market. This disclosure complies with PIT Regulation 7(2).
- Value
- ₹11.94 Cr
Symbiotec Pharmalab Business Update
Symbiotec Pharmalab received an Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur manufacturing facility. The inspection concluded with a Voluntary Action Indicated (VAI) classification.
- From
- U.S. Food and Drug Administration (U.S. FDA)
Other other announcement announcements
All →Cellecor Gadgets Other Announcement
Cellecor Gadgets filed its half-yearly secretarial compliance report for April–September 2026. All compliance checks returned nil deviations with no regulatory actions.
Himalaya Nutravedics India Other Announcement
Himalaya Nutravedics India Ltd intimated BSE of its updated CIN and MCA master data after listing on the BSE SME Platform. The filing is a routine administrative record update with no financial or operational impact.
HRS Aluglaze Other Announcement
HRS Aluglaze filed its final MA report confirming IPO proceeds of ₹50.92 Crore utilised without deviation. The filing is a routine Reg 32/ICDR 41 compliance certificate with no new business event.
B.D. Industries (Pune) Other Announcement
B. D. Industries (Pune) filed its half-yearly shareholding pattern as of 30 September 2026. This is a routine Regulation 31 compliance statement with no transaction or business event.
Patel Chem Specialities Other Announcement
Patel Chem Specialities filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 68.9% of the company's shares.
Transwind Infrastructures Other Announcement
Transwind Infrastructures informed NSE that Regulation 23(9) related-party-transaction disclosure is not applicable for Q1 FY27. As an SME-platform listed entity, the company is exempt from the XBRL RPT filing requirement.